Core Insights - The National Medical Products Administration (NMPA) reported that as of the first half of this year, there are 272 new cosmetic raw materials registered and filed in China, indicating a steady growth trend [1] Industry Summary - The introduction of new raw materials signifies new functional elements, which enhance product competitiveness and brand influence [1] - The promotion of research and development of Chinese characteristic plant materials is crucial for expanding the influence and competitiveness of Chinese cosmetics in the international market [1]

Core Viewpoint - The National Medical Products Administration (NMPA) reports a steady increase in the registration and filing of new cosmetic raw materials in China, with a total of 272 new materials expected by June 2025 [1] Group 1: Regulatory Changes - Since the implementation of the Cosmetic Supervision and Administration Regulations in 2021, significant adjustments have been made to the management of new cosmetic raw materials in China [1] - New raw materials are categorized based on their risk levels, with higher-risk materials requiring registration and others subject to filing management [1] Group 2: Support for Innovation - The NMPA is actively supporting innovation in cosmetic raw materials by optimizing the registration and filing processes [1] - There is an emphasis on enhancing the internal motivation for innovation among companies while ensuring quality and safety standards are maintained [1]

Core Insights - Shenzhen has introduced new legislation aimed at promoting the innovation and development of the synthetic biology industry, addressing key challenges such as supply chain coordination and long approval cycles for new materials [1][5]. Group 1: Legislative Developments - The draft regulations consist of 30 articles and aim to tackle common pain points in the synthetic biology industry, including supply chain issues and the lengthy approval process for new materials [1]. - The regulations will be open for public consultation until June 13, indicating a collaborative approach to policy-making [1]. Group 2: Market Potential - According to McKinsey, the global bioeconomy is projected to reach $2 trillion to $4 trillion in the next 10-20 years, with the contribution of biological modification expected to rise to 30%-70% over time [1][4]. - In China, 40% of newly established synthetic biology companies in the past three years are concentrated in Shenzhen, highlighting the city's growing significance in this sector [1][5]. Group 3: Industry Collaboration - The draft regulations emphasize collaboration with national and provincial health departments to enhance the safety assessment of new food materials and additives [3]. - The regulations also aim to improve the efficiency of the approval process for new cosmetic ingredients, addressing existing challenges such as high costs and long timelines [2][3]. Group 4: Support Mechanisms - Shenzhen plans to establish specialized industrial parks for synthetic biology, providing necessary R&D and production facilities, as well as public technical services [5][6]. - The city will support higher education institutions in offering programs related to synthetic biology and encourage partnerships between academia and industry to cultivate talent [5][6]. Group 5: Financial Initiatives - The Shenzhen government will leverage investment funds to support small and medium-sized enterprises in the synthetic biology sector, enhancing access to financing for startups [6]. - A private equity fund focused on synthetic biology was established in Shenzhen with a scale of 1.5 billion yuan, and local banks have increased credit limits for startups in this field [6].